[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.154.210. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
March 22/29, 2000

The Origins of Alzheimer DiseaseA Is for Amyloid

Author Affiliations

Author Affiliation: Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Mass.

JAMA. 2000;283(12):1615-1617. doi:10.1001/jama.283.12.1615

Few public health problems have captured the attention of the biomedical and lay communities alike as has Alzheimer disease (AD). As the new millennium begins, it is becoming increasingly clear that a great many people will escape other major causes of mortality to reach the age when neurodegenerative diseases, particularly AD, become highly prevalent. To avoid an exacerbation of the personal and societal tragedy that AD already represents, clinicians and researchers must accurately define its cause and early pathogenesis and develop effective interventions, preferably agents that prevent the onset of symptoms. The study by Näslund et al1 in this issue of THE JOURNAL provides compelling evidence that the accumulation of small protein fragments called amyloid β-peptides (Aβ) in brain regions subserving memory and cognition is a very early pathogenic event that precedes both neurological impairment and the development of the other proteinaceous lesion of AD, the neurofibrillary tangle. Moreover, the authors show that the conversion from a presymptomatic to a symptomatic state and the subsequent progression of dementia correlate significantly with a dramatic increase in brain Aβ levels.

First Page Preview View Large
First page PDF preview
First page PDF preview
×